Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
Decisions and readouts loom for the SERDs Astra’s camizestrant and Roche’s giredestrant.
But biomarker enrichment and toxicity remain key for FX-909.
The first fruit of a long-standing deal with Roche enters phase 1 in March.
An FDA verdict is due in the third quarter, as Protagonist looks likely to opt out.
The month saw the first commissioner's priority voucher approval in oncology.
Welireg looks headed to regulators in second-line and adjuvant kidney cancer.
